biostudies-literatureBowman PNIDDK NIH HHSNational Institute of Diabetes and Digestive and Kidney DiseasesDiabetes UKNational Institute for Health Research (NIHR)Wellcome TrustNovo Nordisk Fonden35-42https://www.ebi.ac.uk/biostudies/studies/S-EPMC7783935biostudies-literatureUnknown44(1)<h4>Objective</h4><i>ABCC8</i> mutations cause neonatal diabetes mellitus that can be transient (TNDM) or, less commonly, permanent (PNDM); ∼90% of individuals can be treated with oral sulfonylureas instead of insulin. Previous studies suggested that people with <i>ABCC8-</i>PNDM require lower sulfonylurea doses and have milder neurological features than those with <i>KCNJ11-</i>PNDM. However, these studies were short-term and included combinations of <i>ABCC8</i>-PNDM and <i>ABCC8</i>-TNDM. We aimed to assess the long-term glycemic and neurological outcomes in sulfonylurea-treated <i>ABCC8</i>-PNDM.<h4>Research design and methods</h4>We studied all 24 individuals with <i>ABCC8-</i>PNDM diagnosed in the U.K., Italy, France, and U.S. known to transfer from insulin to sulfonylureas before MaDiabetes careLong-term Follow-up of Glycemic and Neurological Outcomes in an International Series of Patients With Sulfonylurea-Treated &lt;i&gt;ABCC8&lt;/i&gt; Permanent Neonatal Diabetes.PMC7783935R01-DK-104942NF-SI-0611-1021919/00597116/0005407PDA/02/06/098NIHR4-SNMRL058091985105636/Z/14/ZR01 DK104942P30 DK02059519/0005971P30-DK-020595098395/Z/12/ZNNF18OC0054741105636Greeley KWNeonatal Diabetes International Collaborative GroupRusso LFord TSanchez JCodner EKumaraguru Pillai JDarendeliler FWerner AChakera ALeGault LDankovcikova ABarbetti FStanik JRawlins EBeltrand JNjolstad PLetourneau-Freiberg LRAmratlal Patel KAydin BHattersley ATVoorhoeve PSanchez JCCummings EFinn RJain VBowman PBabiker TBauer KEGallardo VMathews FEllard SRaceala-Motoc SSchebek MMohsin FGreeley SAWBas FHeffernan EShepherd MHSulen APiccini BRafiq MHoughton JRaile KIovane BDe Galan BDe Franco EBundak RFlanagan SEThomas NJPolak MPunthakee ZVan Der Meulen JGasperikova DfalseLong-term Follow-up of Glycemic and Neurological Outcomes in an International Series of Patients With Sulfonylurea-Treated &lt;i&gt;ABCC8&lt;/i&gt; Permanent Neonatal Diabetes.<h4>Objective</h4><i>ABCC8</i> mutations cause neonatal diabetes mellitus that can be transient (TNDM) or, less commonly, permanent (PNDM); ∼90% of individuals can be treated with oral sulfonylureas instead of insulin. Previous studies suggested that people with <i>ABCC8-</i>PNDM require lower sulfonylurea doses and have milder neurological features than those with <i>KCNJ11-</i>PNDM. However, these studies were short-term and included combinations of <i>ABCC8</i>-PNDM and <i>ABCC8</i>-TNDM. We aimed to assess the long-term glycemic and neurological outcomes in sulfonylurea-treated <i>ABCC8</i>-PNDM.<h4>Research design and methods</h4>We studied all 24 individuals with <i>ABCC8-</i>PNDM diagnosed in the U.K., Italy, France, and U.S. known to transfer from insulin to sulfonylureas before Ma2021-01-01T00:00:00Z2021 Jan2026-06-06T22:48:57.528Z2026-06-06T03:11:06.859ZS-EPMC77839353318415010.2337/dc20-1520